Rivaroxaban
ریواروکسابان
🩸 Blood And Blood Forming OrgansOral anticoagulant (factor Xa inhibitor)
Market / country: 🇺🇸 USA
Xarelto (US)
🧮 Dose calculator
Atrial fibrillation / anticoagulation · Regimen source: FDA Xarelto · 2.1
- • 15 or 20 mg depending on creatinine clearance. 15 and 20 mg tablets with food. FDA Xarelto · 2FDA Xarelto · 2.1
Enter age (weight is optional for this regimen).
🛡️ Safety & information
Contraindications
- ⛔ Active pathological bleeding; severe hypersensitivity. FDA Xarelto · 4
- ⚠️ Boxed warning: premature discontinuation raises thrombotic risk; spinal/epidural haematoma with neuraxial anaesthesia. FDA Xarelto · Boxed Warning
Formulations
- 2.5 mg tablet — tablet 🇺🇸 USA FDA Xarelto · 3
- 10 mg tablet — tablet 🇺🇸 USA FDA Xarelto · 3
- 15 mg tablet — tablet 🇺🇸 USA FDA Xarelto · 3
- 20 mg tablet — tablet 🇺🇸 USA FDA Xarelto · 3
👥 Special populations
- 🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Xarelto · 8.1
“Risk Summary The limited available data on XARELTO in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes.”
- 🤱 BreastfeedingUse with caution
Label: use with caution while breastfeeding; see the label text. FDA Xarelto · 8.2
“Risk Summary Rivaroxaban has been detected in human milk.”
- 👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Xarelto · 8.4
“The safety and effectiveness of XARELTO have been established in pediatric patients from birth to less than 18 years for the treatment of VTE and the reduction in risk of recurrent VTE.”
- 👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Xarelto · 8.5
“Of the total number of adult patients in clinical trials for the approved indications of XARELTO (N=64,943 patients), 64 percent were 65 years and over, with 27 percent 75 years and over.”
- ⚥ Females & males of reproductive potentialUse with caution
Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Xarelto · 8.3
“Females of reproductive potential requiring anticoagulation should discuss pregnancy planning with their physician.”
🔗 Reference links
- FDA (approval record)NDA022406
- DailyMed (FDA label)FDA Xarelto
- MedlinePlus (NIH)Rivaroxaban
- WHO ATC/DDDB01AF01
- Darooyab (Iran)Rivaroxaban
🇮🇷 Registered in Iran Darooyab · G-4798/Rivaroxaban
Dosage forms with Iranian generic codes, per Darooyab.
- 17597 · RIVAROXABAN 10MG TAB · قرص ریواروکسابان ۱۰ میلیگرم
- 22856 · RIVAROXABAN 20MG TAB · قرص ریواروکسابان ۲۰ میلیگرم
- 50005 · RIVAROXABAN 15MG TAB · قرص ریواروکسابان ۱۵ میلیگرم
- 52235 · RIVAROXABAN 2.5MG TAB · قرص ریواروکسابان ۲٫۵ میلیگرم
📚 Reference status for this drug
Shows which sources have references recorded for this drug and which do not.
- FDA label (DailyMed)✅ PresentFDA Xarelto · 3FDA Xarelto · 2.1FDA Xarelto · 2FDA Xarelto · 4FDA Xarelto · Boxed WarningFDA Xarelto · 8.1FDA Xarelto · 8.2FDA Xarelto · 8.4FDA Xarelto · 8.5FDA Xarelto · 8.3FDA Xarelto · SPL approval / marketing category
- UK SmPC (eMC / MHRA)❌ Not present
- Published guideline❌ Not present
- Licensed reference (medical school)❌ Not present
- Iranian leaflet (IFDA)❌ Not present
- Pharmacy website (secondary, unreliable)✅ PresentDarooyab · G-4798/Rivaroxaban
- Clinical review⚠ Unverified